Pharmacogenetics of ophthalmic topical β-blockers

Duska J. Sidjanin, Catherine A. McCarty, Richard Patchett, Edward Smith, Russell A. Wilke

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical β-blockers. This review summarizes clinically significant polymorphisms that have been identified in the β-adrenergic receptors (ADRB1, ADRB2 and ADRB3). The implications of polymorphisms in CYP2D6 are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basi5 of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical β-blockers may advance individualized treatment at a lower cost.

Original languageEnglish (US)
Pages (from-to)377-385
Number of pages9
JournalPersonalized Medicine
Issue number4
StatePublished - 2008


  • CYP2D6
  • Glaucoma
  • IOP
  • Polymorphisms
  • Timolol
  • β-adrenergic receptor
  • β-blocker


Dive into the research topics of 'Pharmacogenetics of ophthalmic topical β-blockers'. Together they form a unique fingerprint.

Cite this